Stat3 Signaling in Prostate Cancer Progression and Therapy Resistance: An Oncogenic Pathway With Diverse Functions Publisher Pubmed



Sadrkhanloo M^{1, 3} ; Paskeh MDA^{2, 3} ; Hashemi M^{2, 3} ; Raesi R^{4, 5} ; Motahhary M⁶ ; Saghari S⁷ ; Sharifi L⁸ ; Bokaie S⁹ ; Mirzaei S¹⁰ ; Entezari M^{2, 3} ; Aref AR^{11, 12} ; Salimimoghadam S¹³ ; Rashidi M^{14, 15} ; Taheriazam A^{3, 16} Show All Authors Show Affiliations
Source: Biomedicine and Pharmacotherapy Published:2023

Abstract

The categorization of cancers demonstrates that prostate cancer is the most common malignancy in men and it causes high death annually. Prostate cancer patients are diagnosed mainly via biomarkers such as PSA test and patients show poor prognosis. Prostate cancer cells rapidly diffuse into different parts of body and their metastasis is also a reason for death. Current therapies for prostate cancer patients include chemotherapy, surgery and radiotherapy as well as targeted therapy. The progression of prostate cancer cells is regulated by different factors that STAT3 signaling is among them. Growth factors and cytokines such as IL-6 can induce STAT3 signaling and it shows carcinogenic impact. Activation of STAT3 signaling occurs in prostate cancer and it promotes malignant behavior of tumor cells. Induction of STAT3 signaling increases glycolysis and proliferation of prostate cancer cells and prevents apoptosis. Furthermore, STAT3 signaling induces EMT mechanism in increasing cancer metastasis. Activation of STAT3 signaling stimulates drug resistance and the limitation of current works is lack of experiment related to role of STAT3 signaling in radio-resistance in prostate tumor. Calcitriol, capsazepine and β-elemonic are among the compounds capable of targeting STAT3 signaling and its inhibition in prostate cancer therapy. In addition to natural products, small molecules targeting STAT3 signaling have been developed in prostate cancer therapy. © 2023 The Authors